Tag: PALFORZIA

June 1, 2020 Off

New PALFORZIA™ Data on Long-Term Safety, Efficacy and Immunomodulation and New Data on Patient Satisfaction with PALFORZIA Treatment to be Presented at EAACI 2020 Congress

— Important Data on Psychosocial Burden of Peanut Allergy on Children and Caregivers Also to be Presented — BRISBANE, Calif.–(BUSINESS…

September 13, 2019 Off

Aimmune gets FDA Allergenic Products Advisory committee’s support the use of its Palforzia for peanut allergy

By BusinessWire

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that the Allergenic Products Advisory Committee (APAC) convened by the U.S. Food and Drug Administration (FDA) voted to support the use of AR101 (proposed trade name PALFORZIA™) in children and teens with peanut allergy.